Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesUCB"s Cimzia Approved in the U.S. for Adult Patients Suffering from Moderate to Severe Rheumatoid Arthritis
-- Enzon to receive royalties for PEGylation technology--
Enzon Pharmaceuticals, 05/15/09
Enzon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia, for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Cimzia, is a PEGylated anti-TNFa. The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon's PEGylation technology, including PEG-INTRON, Macugen, and Pegasys.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor